Advaxis Immunotherapy Boosts 12-Month Survival In Cervical Cancer
This article was originally published in Scrip
Executive Summary
Advaxis Inc. reported that 38.5% of advanced cervical cancer patients – a group that normally survives for four to seven months on average – survived for at least 12 months after treatment with the company's immunotherapy axalimogene filolisbac (ADXS-HPV) in the first stage of a 67-patient, investigator-initiated, two-stage Phase II clinical trial.
You may also be interested in...
Advaxis Zips Listeria/Opdivo Combo Straight To Registrational Cervical Cancer Trial
Potentially registrational trial of ADXS-DUAL Listeria-based vaccine with Bristol's PD-1 inhibitor Opdivo in recurrent metastatic cervical cancer will complement Advaxis's adjuvant study of earlier-generation candidate axalimogene filolisbac.
Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost
Advaxis is developing – now with help from partner Amgen – a personalized immunotherapy strategy with each patient's cancer vaccine based on their own tumor's specific neoepitopes.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.